Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harvey Phillips

Gastroenterology Fernandina Beach, FL Medical Doctor

NPI 1134228893 CMS profile 50891

1348 South 18Th Street, Suite 100, Fernandina Beach, FL 32034

Open in the dashboard

General payments

$11,649

557 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harvey Phillips of Fernandina Beach, FL is reported in the CMS Open Payments database as having received $11,649 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,677 112
2024 General $2,582 118
2023 General $1,692 78
2022 General $1,517 81
2021 General $888 53
2020 General $535 28
2019 General $1,757 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harvey Phillips
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Harvey Phillips were reported at $2,677. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Harvey Phillips Gastroenterology median Middle half National median
2019 $1,757 $417 $126–$1,100 $163
2020 $535 $224 $74–$624 $114
2021 $888 $352 $106–$1,054 $132
2022 $1,517 $448 $129–$1,270 $149
2023 $1,692 $533 $150–$1,390 $160
2024 $2,582 $605 $160–$1,606 $164
2025 $2,677 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,864 141 payments
  2. Janssen Biotech, Inc. $1,813 66 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,322 78 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $782 45 payments
  5. Madrigal Pharmaceuticals $779 35 payments
  6. Genzyme Corporation $558 21 payments
  7. Pfizer Inc. $472 33 payments
  8. Celgene Corporation $307 27 payments
  9. Covidien LP $291 3 payments
  10. Lilly USA, LLC $262 16 payments
  11. Other $2,200 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,331 552 payments
  2. Travel and Lodging $291 3 payments
  3. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,347 52 payments
  2. XIFAXAN $1,159 68 payments
  3. CREON $959 42 payments
  4. RINVOQ $930 41 payments
  5. TREMFYA $873 18 payments
  6. HUMIRA $633 35 payments
  7. REZDIFFRA $597 24 payments
  8. DUPIXENT $558 21 payments
  9. LINZESS $537 38 payments
  10. SKYRIZI $473 26 payments
  11. Other $5,514 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,210

Median for Gastroenterology: 569

Drug cost

$653,999

Median for Gastroenterology: $104,976

Branded share of claims

40.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 11 $287,232
Zenpep Lipase/Protease/Amylase Brand 28 $127,874
Creon Lipase/Protease/Amylase Brand 23 $66,632
Linzess Linaclotide Brand 56 $53,131
Xifaxan Rifaximin Brand 17 $48,637
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 115 $18,714
Mesalamine Generic 21 $17,463
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 114 $7,252
Mesalamine Er Mesalamine Brand 30 $5,279
Pantoprazole Sodium Generic 291 $3,637

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$144,914

Medicare's payments for the services billed

Medicare patients

693

Average age 74

Services billed

1,556

356 women, 337 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 38%
Chronic kidney disease 28%
Diabetes 27%
Depression 25%
Atrial fibrillation 20%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $263
$263 11 —
DUPIXENT
  • GENZYME CORPORATION $183
  • Regeneron Healthcare Solutions, Inc. $24
$206 — —
TREMFYA
  • Janssen Biotech, Inc. $180
$180 — —
OMVOH
  • Lilly USA, LLC $149
$149 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $123
$123 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record